ArticleJournal of orthopaedic case reports2026
Efficacy of Tranexamic Acid in Reducing Blood Loss and Transfusion Requirements in Primary Total Knee Arthroplasty: A Prospective Comparative Study.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Total knee arthroplasty (TKA) is associated with significant perioperative blood loss, often necessitating blood transfusion. Tranexamic acid (TXA), an antifibrinolytic agent, has been shown to reduce bleeding effectively. This study evaluated the efficacy and safety of intravenous TXA in reducing perioperative blood loss in patients undergoing primary unilateral TKA. Materials and Methods: This prospective randomized controlled trial included 60 patients with Kellgren-Lawrence Grade 3 or 4 osteoarthritis undergoing primary unilateral TKA at a tertiary care center. Patients were randomized into two groups: The TXA group (n = 30) received 1g intravenous TXA before tourniquet release, while the control group (n = 30) received normal saline. Outcome measures included intraoperative blood loss, post-operative drain output, hemoglobin changes, and transfusion requirements. Results: The TXA group demonstrated significantly lower intraoperative blood loss (205.33 vs. 305.67 mL, P < 0.001), total drain output (185.00 vs. 298.33 mL, P < 0.001), and proportional hemoglobin loss (14.19% vs. 19.98%, P < 0.001). Transfusion requirements were significantly reduced in the TXA group (6.67% vs. 26.67%, P = 0.039). No thromboembolic complications were observed in either group. Conclusion: Intravenous TXA significantly reduces perioperative blood loss and transfusion requirements in TKA without increasing thromboembolic risk, supporting its routine use in blood conservation protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.